查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2135506

類病毒顆粒疫苗市場：全球市場預測（2026-2032年）

Virus like Particle Vaccines Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，類病毒顆粒疫苗市場將成長至 16.8 億美元，複合年成長率為 6.98%。

主要市場統計數據
基準年 2025 10.4億美元
預計年份：2026年 11.1億美元
預測年份 2032 16.8億美元
複合年成長率 (%) 6.98%

類病毒顆粒（VLP）疫苗：概述

類病毒顆粒（VLP）疫苗利用非感染性顆粒模擬病毒的關鍵結構特徵，但不具備可複製的基因組。這種設計能夠以重複且高度有序的方式呈現抗原，從而促進免疫識別，同時避免了活病毒疫苗和可複製病毒疫苗的相關風險。此領域涵蓋預防性疫苗、平台技術、生產系統、佐劑策略和分析技術。

平台創新正在改變VLP疫苗的研發方式。

發展方向正轉向能夠呈現多種病原體抗原的模組化病毒樣顆粒（VLP）平台，從而實現對新出現的變異株的快速適應。重組表達系統、基於結構的抗原設計、顆粒工程、純化和表徵等方面的進步正在提升產品品管。然而，仍有許多挑戰，包括批次間一致性、規模化生產、冷鏈要求、監管相容性以及在不同人群中驗證其持續預防功效的必要性。

人工智慧加速抗原和製程的確定。

人工智慧在病毒樣顆粒（VLP）疫苗研究中發揮日益重要的作用，其應用包括蛋白質結構預測、抗原決定基選擇、序列最佳化、製劑篩檢和免疫反應數據分析。機器學習工具可用於確定構建體的優先順序並識別用於後續實驗室測試的程式參數，但其價值取決於可靠的訓練資料和實驗檢驗。在生物安全、轉化解釋、監管文件編制以及意外免疫效應評估方面，人為監督仍然至關重要。

區域洞察：不同地區的功能和訪問要求各不相同。

北美擁有先進的生物技術基礎設施、臨床研究能力和成熟的監管經驗。歐洲受益於強大的學術網路、協調的公共衛生體系和生產能力。同時，亞太地區在多元化的法規環境下，正不斷拓展研究、生物加工和疫苗生產能力。拉丁美洲致力於增強區域供應鏈的韌性，並提昇技術獲取管道。中東正在發展生命科學和免疫接種領域的基礎設施，而非洲則繼續優先發展在地化生產、人力資源發展、監測和公平取得。在所有地區，技術轉移和可靠的品管系統都是實現永續部署的關鍵。

團隊洞察：協作塑造平台部署

東協合作涵蓋區域製造業、監管協調和准入規劃，而金磚國家合作則支持科學研究交流、生產夥伴關係和供應鏈韌性。歐盟為科學研究和採購提供協調一致的政策和法律規範，七國集團成員國在科學、金融和公共衛生領域貢獻了重要力量。海灣合作理事會成員國正在投資醫療衛生和生物技術基礎設施，而北約成員國在戰備、韌性供應鏈和生物威脅防護方面擁有通用利益。由於這些組織在管治和資源方面存在差異，互通性和透明度至關重要。

國家洞察：國家優先事項塑造多樣化的生態系統

美國和加拿大擁有強大的生物醫學和轉化研究生態系統。德國、法國、義大利、西班牙和英國在緊密協調的歐洲框架內，在學術、產業、監管和臨床領域貢獻力量。中國、日本、韓國、印度和澳洲正透過各自的體制模式來推動疫苗研究、生物製造和公共衛生能力建構。巴西和墨西哥為拉丁美洲的區域研究、生產和免疫體係做出了重要貢獻。俄羅斯保持其科學研究和生產能力，但市場進入、監管完整性、供應連續性以及與公共部門的夥伴關係仍然是所有這些國家的重要考量。

領導者的首要任務：建構一個檢驗、適應性強且公平的平台。

產業領導者應優先考慮能夠快速替換抗原且不影響可比較性或安全性的平台設計。他們還應投資於強大的分析表徵、可擴展的表達和純化製程、可靠的製劑和穩定性研究，以及與監管機構的早期溝通。與公共衛生機構和本地製造商建立夥伴關係可以促進臨床試驗的招募、技術轉移和藥物取得。此外，各組織也應建立負責任的人工智慧（AI）管治，包括記錄資料集、檢驗方案、網路安全措施，以及明確模型驅動決策的課責。

調查方法：基於證據的VLP疫苗現況綜合分析。

本執行摘要定性地整合了關於病毒樣顆粒（VLP）疫苗的生物學、研發、生產、監管、人工智慧應用以及區域能力等方面的現有科學和公共衛生知識。研究結果按特定區域、國家組和各國進行分類，並指出了通用的促進因素和阻礙因素。本摘要不包含市場規模估算、市場規模計算、市場佔有率、預測或任何公司的具體聲明。在解讀本摘要時，應結合最新的同行評審研究、監管出版刊物、臨床試驗記錄以及國家免疫和生產計劃。

結論：雖然 VLP 平台提供了策略柔軟性，但它們的實施也面臨挑戰。

病毒樣顆粒（VLP）疫苗為以有序、非感染性的形式呈現抗原提供了一個極具前景的框架，有望支持身體對不斷演變的病原體需求做出適應性免疫反應。其深遠影響取決於可重複的生產流程、嚴謹的臨床證據、有效的監管、可靠的供應鏈以及公平的取得途徑。雖然人工智慧可以改善優先排序和流程開發，但它無法取代實驗檢驗或公共衛生判斷。那些能夠將平台柔軟性與嚴格的品管和協作實施相結合的領導者，將最有能力負責任地推動該領域的發展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：類病毒顆粒疫苗市場：依適應症分類

  • B型肝炎
  • HPV
    • 二價
    • 九價
    • 四價
  • 流感
    • 四價
    • 三價
  • 諾羅病毒

第8章：類病毒顆粒疫苗市場：依疫苗類型分類

  • 為了預防
  • 治療

第9章：類病毒顆粒疫苗市場：依平台類型分類

  • 嵌合體體
  • 重組
  • 合成

第10章：類病毒顆粒疫苗市場：依給藥途徑分類

  • 肌肉內部
  • 鼻內
  • 口服
  • 皮下

第11章：類病毒顆粒疫苗市場：以最終用戶分類

  • 學術研究機構
  • 診所
  • 醫院
  • 製藥和生物技術公司

第12章：類病毒顆粒疫苗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：類病毒顆粒疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：類病毒顆粒疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AstraZeneca
  • Bavarian Nordic
  • BravoVax
  • GeoVax, Inc.
  • GlaxoSmithKline plc
  • HilleVax
  • Medicago Inc.
  • Merck & Co., Inc.
  • Novavax, Inc.
  • Redbiotec AG
  • VBI Vaccines Inc.
  • VLP Therapeutics

第17章 主要專家

Product Code: MRR-961F26FD648B

The Virus like Particle Vaccines Market is projected to grow by USD 1.68 billion at a CAGR of 6.98% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.04 billion
Estimated Year [2026] USD 1.11 billion
Forecast Year [2032] USD 1.68 billion
CAGR (%) 6.98%

Virus-Like Particle Vaccines: Executive Overview

Virus-like particle (VLP) vaccines use noninfectious particles that imitate key structural features of viruses without carrying a replicating genome. This design can present antigens in a repetitive, highly organized form, supporting immune recognition while avoiding the risks associated with live or replication-competent viral vaccines. The field spans preventive vaccines, platform technologies, manufacturing systems, adjuvant strategies, and analytical methods.

Platform Innovation Is Reshaping VLP Vaccine Development

Development is shifting toward modular VLP platforms that can display antigens from multiple pathogens and support faster adaptation to emerging variants. Progress in recombinant expression systems, structure-guided antigen design, particle engineering, purification, and characterization is improving control over product quality. Key challenges remain, including consistency across batches, scale-up, cold-chain requirements, regulatory comparability, and the need to demonstrate durable protection in diverse populations.

Artificial Intelligence Accelerates Antigen and Process Decisions

Artificial intelligence is increasingly relevant to VLP vaccine research through protein-structure prediction, epitope selection, sequence optimization, formulation screening, and analysis of immune-response data. Machine-learning tools can help prioritize constructs and identify process parameters for further laboratory testing, but their value depends on reliable training data and experimental validation. Human oversight remains essential for biosafety, translational interpretation, regulatory documentation, and the assessment of unexpected immune effects.

Regional Insights: Capabilities and Access Conditions Differ

North America combines advanced biotechnology infrastructure, clinical research capacity, and established regulatory expertise. Europe benefits from strong academic networks, coordinated public-health systems, and manufacturing capabilities, while Asia-Pacific is expanding research, bioprocessing, and vaccine-production capacity across varied regulatory environments. Latin America is focused on strengthening regional supply resilience and technology access. The Middle East is developing life-science and immunization infrastructure, and Africa continues to prioritize local manufacturing, workforce development, surveillance, and equitable access. Across all regions, technology transfer and dependable quality systems are central to sustainable deployment.

Group Insights: Cooperation Shapes Platform Adoption

ASEAN cooperation is relevant to regional manufacturing, regulatory alignment, and access planning, while BRICS collaboration can support research exchange, production partnerships, and supply resilience. The European Union provides a coordinated policy and regulatory context for research and procurement, and G7 members contribute substantial scientific, financial, and public-health capabilities. GCC countries are investing in healthcare and biotechnology infrastructure, whereas NATO members have a shared interest in preparedness, resilient supply chains, and protection against biological threats. These groups differ in governance and resources, making interoperability and transparent standards important.

Country Insights: National Priorities Create a Diverse Ecosystem

The United States and Canada maintain strong biomedical research and translational ecosystems. Germany, France, Italy, Spain, and the United Kingdom contribute academic, industrial, regulatory, and clinical capabilities within a closely connected European landscape. China, Japan, South Korea, India, and Australia are advancing vaccine research, biomanufacturing, and public-health capacity through different institutional models. Brazil and Mexico are important Latin American contributors to regional research, production, and immunization systems. Russia retains scientific and manufacturing capabilities, while market access, regulatory alignment, supply continuity, and public-sector partnerships remain important considerations across all listed countries.

Priorities for Leaders: Build Validated, Adaptable, and Equitable Platforms

Industry leaders should prioritize platform designs that support rapid antigen replacement without compromising comparability or safety. They should invest in robust analytical characterization, scalable expression and purification processes, reliable formulation and stability programs, and early engagement with regulators. Partnerships with public-health agencies and regional manufacturers can strengthen clinical recruitment, technology transfer, and access. Organizations should also establish responsible artificial-intelligence governance, including documented datasets, validation protocols, cybersecurity controls, and clear accountability for model-assisted decisions.

Methodology: Evidence-Based Synthesis of the VLP Vaccine Landscape

This executive summary uses a qualitative synthesis of established scientific and public-health knowledge concerning VLP vaccine biology, development, manufacturing, regulation, artificial-intelligence applications, and regional capacity. Findings are organized across the specified regions, country groups, and countries to identify common enablers and constraints. No market estimates, market sizing, market shares, forecasts, or company-specific claims are included. Interpretation should be complemented by current peer-reviewed studies, regulatory publications, clinical-trial records, and national immunization or manufacturing plans.

Conclusion: VLP Platforms Offer Strategic Flexibility with Execution Demands

VLP vaccines provide a promising framework for presenting antigens in an organized, noninfectious format and may support adaptable responses to changing pathogen needs. Their broader impact will depend on reproducible manufacturing, rigorous clinical evidence, effective regulation, dependable supply chains, and equitable access. Artificial intelligence can improve prioritization and process development, but it cannot replace experimental validation or public-health judgment. Leaders that combine platform flexibility with disciplined quality and collaborative implementation will be best positioned to advance the field responsibly.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Virus like Particle Vaccines Market, by Indication

  • 7.1. Introduction
  • 7.2. Hepatitis B
  • 7.3. HPV
    • 7.3.1. Bivalent
    • 7.3.2. Nonavalent
    • 7.3.3. Quadrivalent
  • 7.4. Influenza
    • 7.4.1. Quadrivalent
    • 7.4.2. Trivalent
  • 7.5. Norovirus

8. Virus like Particle Vaccines Market, by Vaccine Type

  • 8.1. Introduction
  • 8.2. Prophylactic
  • 8.3. Therapeutic

9. Virus like Particle Vaccines Market, by Platform Type

  • 9.1. Introduction
  • 9.2. Chimeric
  • 9.3. Recombinant
  • 9.4. Synthetic

10. Virus like Particle Vaccines Market, by Route Of Administration

  • 10.1. Introduction
  • 10.2. Intramuscular
  • 10.3. Intranasal
  • 10.4. Oral
  • 10.5. Subcutaneous

11. Virus like Particle Vaccines Market, by End User

  • 11.1. Introduction
  • 11.2. Academic And Research Institutes
  • 11.3. Clinics
  • 11.4. Hospitals
  • 11.5. Pharma And Biotech Companies

12. Virus like Particle Vaccines Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Virus like Particle Vaccines Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Virus like Particle Vaccines Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AstraZeneca
  • 16.2. Bavarian Nordic
  • 16.3. BravoVax
  • 16.4. GeoVax, Inc.
  • 16.5. GlaxoSmithKline plc
  • 16.6. HilleVax
  • 16.7. Medicago Inc.
  • 16.8. Merck & Co., Inc.
  • 16.9. Novavax, Inc.
  • 16.10. Redbiotec AG
  • 16.11. VBI Vaccines Inc.
  • 16.12. VLP Therapeutics

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Virus like Particle Vaccines Market, Years Considered for the Study
  • FIGURE 2. Global Virus like Particle Vaccines Market, Research Design
  • FIGURE 3. Global Virus like Particle Vaccines Market, Research Framework
  • FIGURE 4. Global Virus like Particle Vaccines Market, Data Triangulation
  • FIGURE 5. Global Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Virus like Particle Vaccines Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 7. Global Virus like Particle Vaccines Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Virus like Particle Vaccines Market Size, by Vaccine Type, 2025 vs 2032 (%)
  • FIGURE 9. Global Virus like Particle Vaccines Market Size, by Vaccine Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Virus like Particle Vaccines Market Size, by Platform Type, 2025 vs 2032 (%)
  • FIGURE 11. Global Virus like Particle Vaccines Market Size, by Platform Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Virus like Particle Vaccines Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 13. Global Virus like Particle Vaccines Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Virus like Particle Vaccines Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global Virus like Particle Vaccines Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Virus like Particle Vaccines Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Virus like Particle Vaccines Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Virus like Particle Vaccines Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Virus like Particle Vaccines Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Virus like Particle Vaccines Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Virus like Particle Vaccines Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Virus like Particle Vaccines Market Segmentation & Coverage
  • TABLE 2. Global Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 4. Global Hepatitis B Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Hepatitis B Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Hepatitis B Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global HPV Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global HPV Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global HPV Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Bivalent Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Bivalent Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Bivalent Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Nonavalent Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Nonavalent Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Nonavalent Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Quadrivalent Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Quadrivalent Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Quadrivalent Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Influenza Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Influenza Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Influenza Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Quadrivalent Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Quadrivalent Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Quadrivalent Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Trivalent Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Trivalent Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Trivalent Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Norovirus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Norovirus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Norovirus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 32. Global Prophylactic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Prophylactic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Prophylactic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Therapeutic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Therapeutic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Therapeutic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 39. Global Chimeric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global Chimeric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global Chimeric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 43. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 44. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 45. Global Synthetic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Synthetic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Synthetic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 49. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global Intranasal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 53. Global Intranasal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 54. Global Intranasal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 55. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 62. Global Academic And Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Global Academic And Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 64. Global Academic And Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 65. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 67. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 68. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 70. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 71. Global Pharma And Biotech Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Global Pharma And Biotech Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 73. Global Pharma And Biotech Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 74. Global Virus like Particle Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Asia-Pacific Virus like Particle Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. Asia-Pacific Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 77. Asia-Pacific Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 78. Asia-Pacific Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 79. Asia-Pacific Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 80. Asia-Pacific Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 81. Asia-Pacific Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 82. Asia-Pacific Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 83. North America Virus like Particle Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. North America Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 85. North America Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 86. North America Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 87. North America Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 88. North America Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 89. North America Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 90. North America Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 91. Latin America Virus like Particle Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 92. Latin America Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 93. Latin America Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 94. Latin America Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 95. Latin America Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 96. Latin America Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 97. Latin America Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 98. Latin America Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 99. Europe Virus like Particle Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 100. Europe Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 101. Europe Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 102. Europe Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 103. Europe Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 104. Europe Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 105. Europe Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 106. Europe Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 107. Middle East Virus like Particle Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 108. Middle East Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 109. Middle East Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 110. Middle East Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 111. Middle East Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 112. Middle East Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 113. Middle East Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 114. Middle East Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 115. Africa Virus like Particle Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 116. Africa Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 117. Africa Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 118. Africa Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 119. Africa Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 120. Africa Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 121. Africa Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 122. Africa Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 123. Global Virus like Particle Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 124. ASEAN Virus like Particle Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 125. ASEAN Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 126. ASEAN Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 127. ASEAN Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 128. ASEAN Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 129. ASEAN Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 130. ASEAN Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 131. ASEAN Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 132. GCC Virus like Particle Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 133. GCC Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 134. GCC Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 135. GCC Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 136. GCC Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 137. GCC Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 138. GCC Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 139. GCC Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 140. European Union Virus like Particle Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 141. European Union Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 142. European Union Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 143. European Union Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 144. European Union Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 145. European Union Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 146. European Union Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 147. European Union Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 148. BRICS Virus like Particle Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 149. BRICS Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 150. BRICS Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 151. BRICS Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 152. BRICS Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 153. BRICS Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 154. BRICS Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 155. BRICS Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 156. G7 Virus like Particle Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 157. G7 Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 158. G7 Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 159. G7 Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 160. G7 Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 161. G7 Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 162. G7 Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 163. G7 Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 164. NATO Virus like Particle Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 165. NATO Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 166. NATO Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 167. NATO Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 168. NATO Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 169. NATO Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 170. NATO Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 171. NATO Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 172. Global Virus like Particle Vaccines Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 173. United States Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 174. United States Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 175. United States Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 176. United States Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 177. United States Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 178. United States Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 179. United States Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 180. United States Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 181. Canada Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 182. Canada Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 183. Canada Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 184. Canada Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 185. Canada Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 186. Canada Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 187. Canada Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 188. Canada Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 189. Mexico Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 190. Mexico Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 191. Mexico Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 192. Mexico Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 193. Mexico Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 194. Mexico Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 195. Mexico Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 196. Mexico Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 197. Brazil Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 198. Brazil Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 199. Brazil Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 200. Brazil Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 201. Brazil Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 202. Brazil Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 203. Brazil Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 204. Brazil Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 205. United Kingdom Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 206. United Kingdom Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 207. United Kingdom Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 208. United Kingdom Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 209. United Kingdom Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 210. United Kingdom Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 211. United Kingdom Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 212. United Kingdom Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 213. Germany Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 214. Germany Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 215. Germany Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 216. Germany Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 217. Germany Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 218. Germany Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 219. Germany Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 220. Germany Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 221. France Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 222. France Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 223. France Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 224. France Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 225. France Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 226. France Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 227. France Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 228. France Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 229. Russia Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 230. Russia Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 231. Russia Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 232. Russia Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 233. Russia Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 234. Russia Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 235. Russia Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 236. Russia Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 237. Italy Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 238. Italy Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 239. Italy Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 240. Italy Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 241. Italy Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 242. Italy Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 243. Italy Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 244. Italy Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 245. Spain Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 246. Spain Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 247. Spain Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 248. Spain Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 249. Spain Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 250. Spain Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 251. Spain Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 252. Spain Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 253. China Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 254. China Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 255. China Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 256. China Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 257. China Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 258. China Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 259. China Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 260. China Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 261. India Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 262. India Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 263. India Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 264. India Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 265. India Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 266. India Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 267. India Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 268. India Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 269. Japan Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 270. Japan Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 271. Japan Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 272. Japan Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 273. Japan Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 274. Japan Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 275. Japan Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 276. Japan Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 277. Australia Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 278. Australia Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 279. Australia Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 280. Australia Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 281. Australia Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 282. Australia Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 283. Australia Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 284. Australia Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 285. South Korea Virus like Particle Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 286. South Korea Virus like Particle Vaccines Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 287. South Korea Virus like Particle Vaccines Market Size, by HPV, 2017-2032 (USD Million)
  • TABLE 288. South Korea Virus like Particle Vaccines Market Size, by Influenza, 2017-2032 (USD Million)
  • TABLE 289. South Korea Virus like Particle Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 290. South Korea Virus like Particle Vaccines Market Size, by Platform Type, 2017-2032 (USD Million)
  • TABLE 291. South Korea Virus like Particle Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 292. South Korea Virus like Particle Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 293. Global Virus like Particle Vaccines Market Share, by Key Player, 2025
  • TABLE 294. Global Virus like Particle Vaccines Market, Key Experts